Abstract
Health-related quality of life (HRQOL), has been defined as “peoples’ subjective evaluation of the influences of their current health status... on their ability to achieve and maintain a level of overall functioning that allows them to pursue valued life goals and that is reflected in general wellbeing” [1, 2]. Psoriasis is a chronic disease with physical, psychosocial, and economic implications that commonly interfere with patients’ daily functional capacity, and consequently, their quality of life.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM (1999) Psorasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41: 401–407
Shumaker SA, Naughton MJ (1995) The international assessment of health-related quality of life. In: RA Shumaker, R Berzon (eds): The international assessment of health-related quality of life theory, translation, measurement, and analysis. Rapid Communications; New York, 3–10
NPF Survey Panel (2006) http://www.psoriasis.org/files/pdfs/research/2006_spring_survey_panel.pdf
Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE (2001) Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 45(1): 72–76
Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsso B (2002) Epidemiology and Health Services Research: Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 146: 1006–1016
Finlay AY, Ortonne JP (2004) Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cut Med Surg 8: 310–320
Mease PJ, Menter MA (2006) Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 54: 685–704
Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T (2006) Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 54: S101–111
Fortune, DG, Richards HL, Griffiths CEM (2005) Pyschological factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 23: 681–694
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T (2001) The impact of psoriasis on quality of life: results of a 1998 National Psorasis Foundation patient-membership survey. Arch Dermatol 137: 280–284
NPF Survey Panel Fall (2005) http://www.psoriasis.org/files/pdfs/research/2005_fall_survey_panel.pdf
Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Schafer G (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155: 729–736
Yosipovitch G, Tang MBY (2000) Practical management of psoriasis in the elderly. Drugs Aging 19(11): 847–863
Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (2004) Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 50: 24–35
De Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC (1996) Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1’728 patients. Dermatology 193: 300–303
Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR (2003) Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 49: 271–275
NPF Survey Panel Fall 2004: http://www.psoriasis.org/files/pdfs/research/2004_fall_survey_panel.pdf
Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR (2006) The negative impact of psoriasis on the workplace. J Dermatolog Treat 17(1): 24–28
Finlay AY, Coles E (1995) The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 132: 236–244
Schmitt JM, Ford DE (2006) Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 213(2): 102–110
Marchetti A, LaPensee K, An P (1998) A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. Clinical Therapy 20(4): 8518–8569
Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S (2006) An Italian study on psoriasis and depression. Dermatology 212(2): 123–127
Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P (2000) Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 143: 983–991
Gupta MA, Gupta AK (1998) Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139: 846–850
Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A (2000) The depression, anxiety and life satisfaction and affective expression level in psoriasis patients. J Eur Acad Deramtol Venereol 14: 267–271
Gupta MA, Gupta AK (1999) Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis and chronic idiopathic urticaria. Ann NY Acad Sci 885: 394–395
Gupta MA, Gupta AK, Watteel GN (1998) Perceived deprivation of social touch in psoriasis associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis 61: 339–342
Richards HL, Fortune DG, Griffiths CE, Main CJ (2001) The contribution of perceptions of stigmatization to disability in patients with psoriasis. J Psychosom Res 50: 11–15
Fortune DG, Main CJ, O’Sullivan TM, Griffiths CE (1997) Quality of life in psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 137: 755–760
Fortune DG, Main CJ, O’Sullivan TM, Griffiths CE (1997) Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res 42: 467–476
Fortune DG, Richards HL, Kirby B, McElhone K, Markham T, Rogers S, Main CJ, Griffiths CE (2003) Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 139: 752–756
Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D (2002) Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 147: 736–742
Sampogna F, Picardi A, Melchi CF, Pasquini P, Abeni D (2003) The impact of skin diseases on patients: comparing dermatologists’ opinions with research data collected on their patients. Br J Dermatol 148: 989–995
Gupta MA, Gupta AK (1995) Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 34: 700–703
Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D (2006) Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 154: 325–331
Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC (2000) Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm Venereol 80: 272–276
Schmid-Ott G, Kunsebeck HW, Jager B, Sittig U, Hofste N, Ott R, Malewski P, Lamprecht F (2005) Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 85(1): 27–32
Ginsburg IH (1996) The psychosocial impact of skin disease. Dermatol Clin 14: 473–484
Koo J (1996) Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Psychodermatology 14: 485–496
Wahl A, Moum T, Hanestad BR, Wiklund I (1999) The relationship between demographic and clinical variables and quality of life aspects in patients with psoriasis. Qual Life Res 8: 319–326
Higgins E (2000) Alcohol, smoking and psoriasis. Clin Exp Dermatol 25: 108–110
Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS (2006) Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 126: 1480–1489
Ellis CN, Mordin MM, Adler EY (2003) Effects of Alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 4: 131–139
Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A (2005) Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 153: 1192–1199
Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T (2006) Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 54: S101–111
Krueger G, Wooley JM, Zitnik R (2004) The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis. Presented at the 62nd annual meeting of The American Academy of Dermatology, 6–11 Feb 2004, Washington D.C.
Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349: 2014–2022
Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A (2005) Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 53(5): 887–889
Feldman SR, Menter A, Koo JY (2004) Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 150: 317–326
Ortonne J, Shear N, Shumack S, Henninger E (2005) Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatology 5: 13
Koo JY, Kowalksi J, Guenther L, Walker P (2004) Quality of life effect of oral tazarotene in patients with moderate to severe psoriasis as measured by the 12-item psoriasis quality of life questionnaire (PQOL-12). Presented at the 62nd annual meeting of the American Academy of Dermatology; 6–11 Feb 2004, Washington D.C.
Lim C, Brown P (2006) Quality of life in psoriasis improves after standardized administration of narrowband UVB phototherapy. Australas J Dermatol 47(1): 37–40
Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50: 1939–1950
Salek MS, Finlay AY, Lewis JJ, Sumner MI (2004) Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin (Neoral.) Qual Life Res 13: 91–95
Bhosle MJ, Kulkarni A, Feldman S, Balkrishnan R (2006) Quality of life in patients with psoriasis. Health and Quality of Life Outcomes 4: 35
Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA (2003) Methotrexate versus cyclosporin in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349: 658–665
Gottlieb AB, Ford RO, Spellman MC (2003) The efficacy and tolerability of clobetasol proprionate foam 0.05% in the treatment of mild to moderate plaque type psoriasis in nonscalp regions. J Cutan Med Surg 7: 185–192
Gupta MA, Gupta AK (2001) The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol 15: 512–518
Zaghloul SS, Goodfield MJ (2004) Objective Assessment of compliance with psoriasis treatment. Arch Dermatol 104: 408–414
David SE, Ahmed Z, Salek MS, Finlay AY (2005) Does enough quality of life-related discussion occur during dermatology outpatient consultations? Br J Dermatol 153: 997–1000
Feldman S, Behnam S, Behnam S, Koo JY (2005) Involving the patient: Impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol 53: S78–85
Lu Y, Duller P, van der Valk PGM, Kraaimaat FW, van de Kerkhof PC (2003) Helplessness as predictor of perceived stigmatization in patients with psoriasis and atopic dermatitis. Dermatol Psychosom 4: 146–150
de Korte J, van Onselen J, Kownacki S (2005) Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J EurAcad Dermatol Venereol 19(1): 35–41
NPF website, http://www.psoriasis.org/advocacy/s
Gordon K (2005) Patient education and advocacy Groups. Arch Dermatol (141): 80–81
Nijsten T, Rolstad T, Feldman SR, Stern RS (2005) Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol 141: 19–26
Jankowiak B, Krajewska-Kulak E, Baranowska A (2005) The importance of the health education in life quality improvement in patients with psoriasis. Rocz Akad Med Bialmyst 50Suppl 1: 145–147
Fortune DG, Richards HL, Main CJ, Bowcock S, Main CJ, Griffiths CE (2002) A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 146: 458–465
Price, ML, Mottahedin I, Mayo PR (1991) Can psychotherapy help patients with psoriasis? Clin Exp Dermatol 16(2): 114–117
Kabat-Zinn J, Wheeler E, Light T, Skillings A, Scharf M, Cropley T, Hosmer D, Bernhard J (1998) Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergong phototherapy (UVB) and photochemotherapy (PUVA). Psychosomatic Med 60: 625–632
Koblenzer CS (1987) Psychocutaneous disease. Grune and Stratton, Orlando, Florida, US
Britten N, Stevenson FA, Barry CA, Barber N, Bradley CP (2000) Misunderstandings in prescribing decisions in general practice: qualitative study. BMJ 320: 484–488
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Sergay, A.B., Silvan, M., Weinberg, J.M. (2008). Quality of life issues in psoriasis. In: Weinberg, J.M. (eds) Treatment of Psoriasis. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7724-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7724-3_11
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7722-9
Online ISBN: 978-3-7643-7724-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)